CURE CML CONSORTIUM
We are a group of researchers from 19 world-class academic medical centers throughout North America committed to curing chronic myeloid leukemia (CML) through innovative research. Tyrosine kinase inhibitors (TKIs) revolutionized chronic myeloid leukemia (CML) treatment. Despite this, patients continue to struggle with numerous quality of life issues, such as side effects and substantial medication costs. With feedback from advocates and patients, we strive to meet the needs of the CML community.